📖
Long-term safety and efficacy of lumacaftor/ivacaftor in children aged ≥12 months of age with cystic fibrosis: a 96-week open-label study.
Zemanick ET, McColley SA, Linnemann RW, Rayment JH, Harris WT, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Sosnay PR, Ahluwalia N, Liu L, Jennings M, Rosenfeld M

Long-term safety and efficacy of lumacaftor/ivacaftor in children aged ≥12 months of age with cystic fibrosis: a 96-week open-label study.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in ERJ Open Res.

Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Long-term safety and efficacy of lumacaftor/ivacaftor in children aged ≥12 months of age with cystic fibrosis: a 96-week open-label study.
Author / Organization Zemanick ET, McColley SA, Linnemann RW, Rayment JH, Harris WT, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Sosnay PR, Ahluwalia N, Liu L, Jennings M, Rosenfeld M
Subject & Discipline ERJ Open Res
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-120593
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »